Keywords: Celgene, Gloucester, M&A, Istodax, Blood cancer, Allos Thera, Folotyn, Pricing

Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn

Article | 08 December 2009

Print This

Celgene Corp says it has entered into a definitive agreement to acquire fellow USA-based rival acquire Gloucester Pharmaceuticals., in a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in